(S)-N-((3-(3-Fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide, 95.0%, 100mg

4-(Methylamino)-1-(pyridin-3-yl)butan-1-one dihydrochloride, 97%, 100mg

(1R,2R,3S,5R)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol, 98%, 5mg

2-(4-Cyclopropylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 95.0%, 10g

2,5,8,11,14-Pentaoxapentadecane, 95.0%, 500g

4-(2-Bromoethyl)benzoic acid, 95.0%, 25g

4-Bromo-3-chloro-2-iodoaniline, 98.0%, 10g

Ethyl tetrahydropyran-4-ylacetate, 95.0%, 25g

5,7-Dichloroimidazo[1,2-c]pyrimidine, 95.0%, 250mg

methyl 3-oxo-3-(3-thienyl)propanoate, 97%, 1g

2-Bromo-5-(trifluoromethyl)pyridine, 98.0%, 10g

Methyl 4-methyl-2-pentenoate, 96.0%, 25g

p-Cymene>95.0%(GC)500mL